ACTA1 and metabolic dysfunction-associated steatotic liver disease: In turn, NF2 suppresses YAP activity, reducing cell proliferation and lowering the levels of inflammatory and fibrotic markers, such as IL-6, TGF-β1, and α-SMA in NAFLD [155].